Xcell Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	923.01	7,764	1,239	5,436	14,632	6,662
Short-Term Investments	300	35.67	120	120	-	8
Trading Asset Securities	-	1,002	-	-	-	-
Cash & Short-Term Investments	1,223	8,802	1,359	5,556	14,632	6,670
Cash Growth	-89.75%	547.78%	-75.55%	-62.03%	119.39%	701.34%
Accounts Receivable	240.4	54.71	282.87	264.4	159.42	26.28
Other Receivables	290.97	455.24	333.93	368.52	109.59	384.62
Receivables	531.37	509.96	616.8	632.92	269.01	410.9
Inventory	1,719	697.92	804.25	686.9	500.67	680.19
Prepaid Expenses	-	10.6	-	-	-	-
Other Current Assets	471.89	491.19	60.41	339.89	22.45	6.22
Total Current Assets	3,945	10,512	2,840	7,216	15,425	7,767
Property, Plant & Equipment	4,537	4,472	5,355	7,372	7,515	5,773
Long-Term Investments	992.08	1,099	34.78	31.69	19.81	7.93
Other Intangible Assets	733.74	537.35	125.05	307.51	238.75	247.1
Long-Term Accounts Receivable	0	-0	-0	-0	-0	0
Other Long-Term Assets	348.34	269.81	2,113	582.39	503.45	273.4
Total Assets	10,556	16,890	10,468	15,509	23,702	14,068
Accounts Payable	128.69	125.57	133.66	90	227.29	464.82
Accrued Expenses	328.76	295.36	263.38	277.52	244.79	234.77
Short-Term Debt	4,200	3,500	4,000	4,000	4,000	1,400
Current Portion of Long-Term Debt	58.32	87.56	72.5	-	-	20
Current Portion of Leases	534.54	465.62	589.68	449.1	453.31	413.96
Other Current Liabilities	518.09	432.39	383.32	370.56	332.31	3,483
Total Current Liabilities	5,768	4,906	5,443	5,187	5,258	6,017
Long-Term Debt	1,103	1,132	1,148	870	870	2,821
Long-Term Leases	473.56	515.99	695.9	527.77	868.12	252.73
Pension & Post-Retirement Benefits	977.23	693.4	288.17	-	93.87	405.13
Other Long-Term Liabilities	611.6	520.26	510.64	440.67	387.31	3,188
Total Liabilities	8,934	7,769	8,085	7,026	7,477	12,683
Common Stock	5,469	5,459	4,582	4,380	4,376	1,494
Additional Paid-In Capital	58,144	57,993	42,711	39,913	39,860	18,153
Retained Earnings	-63,302	-55,717	-46,071	-36,835	-28,407	-19,358
Comprehensive Income & Other	1,311	1,386	1,162	1,025	395.85	342.59
Total Common Equity	1,622	9,121	2,384	8,483	16,225	632.37
Shareholders' Equity	1,622	9,121	2,384	8,483	16,225	1,385
Total Liabilities & Equity	10,556	16,890	10,468	15,509	23,702	14,068
Total Debt	6,370	5,702	6,506	5,847	6,191	4,907
Net Cash (Debt)	-5,147	3,100	-5,147	-290.75	8,441	1,762
Net Cash Growth	-	-	-	-	378.96%	-
Net Cash Per Share	-470.51	309.85	-581.98	-33.21	1019.25	989.27
Filing Date Shares Outstanding	10.94	10.92	9.16	8.76	8.75	2.99
Total Common Shares Outstanding	10.94	10.92	9.16	8.76	8.75	2.99
Working Capital	-1,823	5,605	-2,602	2,029	10,167	1,750
Book Value Per Share	148.29	835.38	260.10	968.50	1854.01	211.63
Tangible Book Value	888.28	8,584	2,258	8,176	15,986	385.27
Tangible Book Value Per Share	81.21	786.16	246.46	933.39	1826.73	128.94
Land	370.53	370.53	370.53	1,971	1,971	1,971
Buildings	1,268	1,624	1,624	1,624	1,624	1,624
Machinery	1,233	3,320	3,059	2,952	2,433	2,107
Construction In Progress	-	-	-	-	278.4	0.92

Source: S&P Global Market Intelligence. Standard template. Financial Sources.